Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
CL

NASDAQ · CLDX

Celldex Therapeutics, Inc.

Healthcare · Biotechnology

$31.65

Down-$0.53 (-1.65%)

Updated Oct 4, 2026, 8:29 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.86B
P/E ratio
-9.3
Dividend yield
0.00%
52-week range
$27.92 – $45.14
Volume
2.41M
Avg. volume
937.83K

Price performance · CLDX

CLDX price history

1M range · 0 trading sessions · Daily adjusted prices

CLDX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CLDX news

The latest Smart Investors Daily articles mentioning CLDX.

Stock researchCompany · Overview

CLDX research

Overview

Company profile and research snapshot.

Company profile

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
CLDX recent ratings
DateFirmRatingTarget
Oct 2, 2026HC Wainwright & Co.Buy—
Sep 23, 2026Leerink PartnersOutperform—
Sep 23, 2026Morgan StanleyOverweight—
Sep 22, 2026Cantor FitzgeraldOverweight—
Sep 22, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capital requirements of drug development. Celldex Therapeutics (NASDAQ:CLDX) embodies the classic profile of a clinical-stage innovator: a proprietary mast cell inhibitor platform, a robust balance sheet insulated by substantial cash reserves, and multi-indication optionality across severe […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By